- Home
- JANX vs CCS Comparison
JANX vs CCS Comparison
Compare JANX & CCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- CCS
- Stock Information
- Founded
- JANX 2017
- CCS 2000
- Country
- JANX United States
- CCS United States
- Employees
- JANX N/A
- CCS N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- CCS Homebuilding
- Sector
- JANX Health Care
- CCS Consumer Discretionary
- Exchange
- JANX Nasdaq
- CCS Nasdaq
- Market Cap
- JANX 1.7B
- CCS 1.9B
- IPO Year
- JANX 2021
- CCS 2014
- Fundamental
- Price
- JANX $29.41
- CCS $58.77
- Analyst Decision
- JANX Strong Buy
- CCS Buy
- Analyst Count
- JANX 10
- CCS 4
- Target Price
- JANX $77.40
- CCS $80.75
- AVG Volume (30 Days)
- JANX 1.1M
- CCS 329.1K
- Earning Date
- JANX 11-06-2025
- CCS 10-22-2025
- Dividend Yield
- JANX N/A
- CCS 1.97%
- EPS Growth
- JANX N/A
- CCS N/A
- EPS
- JANX N/A
- CCS 6.93
- Revenue
- JANX $10,000,000.00
- CCS $4,157,669,000.00
- Revenue This Year
- JANX N/A
- CCS N/A
- Revenue Next Year
- JANX $89.91
- CCS $8.74
- P/E Ratio
- JANX N/A
- CCS $8.48
- Revenue Growth
- JANX N/A
- CCS N/A
- 52 Week Low
- JANX $21.73
- CCS $50.42
- 52 Week High
- JANX $71.71
- CCS $95.76
- Technical
- Relative Strength Index (RSI)
- JANX 58.15
- CCS 42.05
- Support Level
- JANX $26.96
- CCS $58.88
- Resistance Level
- JANX $29.53
- CCS $60.76
- Average True Range (ATR)
- JANX 2.10
- CCS 1.84
- MACD
- JANX 0.00
- CCS -0.08
- Stochastic Oscillator
- JANX 67.36
- CCS 19.30
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About CCS Century Communities Inc.
Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.